These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 21132014)
1. AXL regulates mesothelioma proliferation and invasiveness. Ou WB; Corson JM; Flynn DL; Lu WP; Wise SC; Bueno R; Sugarbaker DJ; Fletcher JA Oncogene; 2011 Apr; 30(14):1643-52. PubMed ID: 21132014 [TBL] [Abstract][Full Text] [Related]
2. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma. Ou WB; Hubert C; Corson JM; Bueno R; Flynn DL; Sugarbaker DJ; Fletcher JA Neoplasia; 2011 Jan; 13(1):12-22. PubMed ID: 21245936 [TBL] [Abstract][Full Text] [Related]
3. HGF-induced formation of the MET-AXL-ELMO2-DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion. Li W; Xiong X; Abdalla A; Alejo S; Zhu L; Lu F; Sun H J Biol Chem; 2018 Oct; 293(40):15397-15418. PubMed ID: 30108175 [TBL] [Abstract][Full Text] [Related]
4. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma. Zhou S; Liu L; Li H; Eilers G; Kuang Y; Shi S; Yan Z; Li X; Corson JM; Meng F; Zhou H; Sheng Q; Fletcher JA; Ou WB Br J Cancer; 2014 May; 110(10):2479-88. PubMed ID: 24762959 [TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells. Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942 [TBL] [Abstract][Full Text] [Related]
6. Skipping of exon 10 in Shen L; Lei S; Zhang B; Li S; Huang L; Czachor A; Breitzig M; Gao Y; Huang M; Mo X; Zheng Q; Sun H; Wang F Theranostics; 2020; 10(13):5719-5735. PubMed ID: 32483414 [TBL] [Abstract][Full Text] [Related]
7. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells. Vouri M; An Q; Birt M; Pilkington GJ; Hafizi S Oncotarget; 2015 Jun; 6(18):16183-97. PubMed ID: 25980499 [TBL] [Abstract][Full Text] [Related]
8. GAS6-expressing and self-sustaining cancer cells in 3D spheroids activate the PDK-RSK-mTOR pathway for survival and drug resistance. Baumann C; Ullrich A; Torka R Mol Oncol; 2017 Oct; 11(10):1430-1447. PubMed ID: 28675785 [TBL] [Abstract][Full Text] [Related]
9. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Jagadeeswaran R; Ma PC; Seiwert TY; Jagadeeswaran S; Zumba O; Nallasura V; Ahmed S; Filiberti R; Paganuzzi M; Puntoni R; Kratzke RA; Gordon GJ; Sugarbaker DJ; Bueno R; Janamanchi V; Bindokas VP; Kindler HL; Salgia R Cancer Res; 2006 Jan; 66(1):352-61. PubMed ID: 16397249 [TBL] [Abstract][Full Text] [Related]
10. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer. Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030 [TBL] [Abstract][Full Text] [Related]
11. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis. Kirane A; Ludwig KF; Sorrelle N; Haaland G; Sandal T; Ranaweera R; Toombs JE; Wang M; Dineen SP; Micklem D; Dellinger MT; Lorens JB; Brekken RA Cancer Res; 2015 Sep; 75(18):3699-705. PubMed ID: 26206560 [TBL] [Abstract][Full Text] [Related]
12. The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Hector A; Montgomery EA; Karikari C; Canto M; Dunbar KB; Wang JS; Feldmann G; Hong SM; Haffner MC; Meeker AK; Holland SJ; Yu J; Heckrodt TJ; Zhang J; Ding P; Goff D; Singh R; Roa JC; Marimuthu A; Riggins GJ; Eshleman JR; Nelkin BD; Pandey A; Maitra A Cancer Biol Ther; 2010 Nov; 10(10):1009-18. PubMed ID: 20818175 [TBL] [Abstract][Full Text] [Related]
13. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival. Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies. Kariolis MS; Miao YR; Diep A; Nash SE; Olcina MM; Jiang D; Jones DS; Kapur S; Mathews II; Koong AC; Rankin EB; Cochran JR; Giaccia AJ J Clin Invest; 2017 Jan; 127(1):183-198. PubMed ID: 27893463 [TBL] [Abstract][Full Text] [Related]
15. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. Burbridge MF; Bossard CJ; Saunier C; Fejes I; Bruno A; Léonce S; Ferry G; Da Violante G; Bouzom F; Cattan V; Jacquet-Bescond A; Comoglio PM; Lockhart BP; Boutin JA; Cordi A; Ortuno JC; Pierré A; Hickman JA; Cruzalegui FH; Depil S Mol Cancer Ther; 2013 Sep; 12(9):1749-62. PubMed ID: 23804704 [TBL] [Abstract][Full Text] [Related]
16. Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling. Park JS; Lee C; Kim HK; Kim D; Son JB; Ko E; Cho JH; Kim ND; Nan HY; Kim CY; Yoon S; Lee SH; Choi HG Oncotarget; 2016 Dec; 7(50):83308-83318. PubMed ID: 27829217 [TBL] [Abstract][Full Text] [Related]
17. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Leconet W; Larbouret C; Chardès T; Thomas G; Neiveyans M; Busson M; Jarlier M; Radosevic-Robin N; Pugnière M; Bernex F; Penault-Llorca F; Pasquet JM; Pèlegrin A; Robert B Oncogene; 2014 Nov; 33(47):5405-14. PubMed ID: 24240689 [TBL] [Abstract][Full Text] [Related]
18. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo. Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524 [TBL] [Abstract][Full Text] [Related]
19. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer. Mishra A; Wang J; Shiozawa Y; McGee S; Kim J; Jung Y; Joseph J; Berry JE; Havens A; Pienta KJ; Taichman RS Mol Cancer Res; 2012 Jun; 10(6):703-12. PubMed ID: 22516347 [TBL] [Abstract][Full Text] [Related]
20. Endocytic trafficking of GAS6-AXL complexes is associated with sustained AKT activation. Poświata A; Kozik K; Miączyńska M; Zdżalik-Bielecka D Cell Mol Life Sci; 2022 May; 79(6):316. PubMed ID: 35622156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]